BioN­Tech CAR-T man­u­fac­tur­ing change leads to fresh da­ta with vac­cine com­bo, with reg­is­tra­tional tri­al plans: #ES­MO23

MADRID — BioN­Tech is back with new da­ta to sup­port its BNT211 pro­gram in sol­id tu­mors af­ter a man­u­fac­tur­ing tweak. The com­pa­ny is now re­view­ing plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.